We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Roche Holding AG, Anthem, Inc. and Infosys Limited
Read MoreHide Full Article
For Immediate Release
Chicago, IL – January 20, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Roche Holding AG (RHHBY - Free Report) , Anthem, Inc. and Infosys Limited (INFY - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Research Reports for Roche, Anthem and Infosys
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Roche Holding AG (RHHBY), Anthem, Inc. (ANTM), and Infosys Limited (INFY). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Roche have modestly underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+12.8% vs. +17.5%), however, things seem to be improving for it. The Zacks analyst believes that strong growth in Ocrevus, Evrysdi, Tecentriq and Hemlibra helps Roche counter biosimilar competition for several of its legacy drugs. Approval of new drugs is another major positive.
Roche’s Diagnostics segment is likely to continue exhibiting strong performance on the back of new launches in the year ahead. The division is poised to benefit from strong demand for COVID-19 tests as well as other diagnostics platforms. RHHBY performance in the year has been encouraging, with the core pharmaceuticals business showing signs of recovery.
Anthem shares have gained +15.6% over the past six months against the Zacks Medical Health Maintenance Organization industry’s gain of +9.4%. The Zacks analyst believes that strategic buyouts and collaborations, an improving top line as well as an expanded product portfolio is likely to drive Anthem’s long-term growth.
Acquisitions and collaborations have enabled ANTM to boost its Medicare Advantage growth and also strengthened its business portfolio. Momentum in Medicare and Medicaid businesses, coupled with contract wins are expected to drive Anthem’s membership. Escalating costs and a weak balance sheet, however, continue to weigh on its margins and impact financial flexibility.
Shares of Infosys have gained +6.5% in the last three months against the Zacks IT Services industry’s loss of -16.6%. The Zacks analyst believes that Infosys has been benefiting significantly from large deal wins as well as momentum in digital services.
INFY’s sustained focus on Agile Digital and artificial intelligence-driven Core services is a tailwind. Strong demand for its services in cloud, Internet of Things, cyber security, data and analytics is a key driver. Steadily rising anti-outsourcing sentiments in certain parts of the world, higher subcontractor costs and Infosys’ compensation revision have been weighing on margins, though.
Other noteworthy reports we are featuring today include Norfolk Southern Corp. (NSC) and Chipotle Mexican Grill, Inc. (CMG).
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +25.3% per year. So be sure to give these hand-picked 7 your immediate attention.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Roche Holding AG, Anthem, Inc. and Infosys Limited
For Immediate Release
Chicago, IL – January 20, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Roche Holding AG (RHHBY - Free Report) , Anthem, Inc. and Infosys Limited (INFY - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Research Reports for Roche, Anthem and Infosys
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Roche Holding AG (RHHBY), Anthem, Inc. (ANTM), and Infosys Limited (INFY). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Roche have modestly underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+12.8% vs. +17.5%), however, things seem to be improving for it. The Zacks analyst believes that strong growth in Ocrevus, Evrysdi, Tecentriq and Hemlibra helps Roche counter biosimilar competition for several of its legacy drugs. Approval of new drugs is another major positive.
Roche’s Diagnostics segment is likely to continue exhibiting strong performance on the back of new launches in the year ahead. The division is poised to benefit from strong demand for COVID-19 tests as well as other diagnostics platforms. RHHBY performance in the year has been encouraging, with the core pharmaceuticals business showing signs of recovery.
(You can read the full research report on Roche here >>>)
Anthem shares have gained +15.6% over the past six months against the Zacks Medical Health Maintenance Organization industry’s gain of +9.4%. The Zacks analyst believes that strategic buyouts and collaborations, an improving top line as well as an expanded product portfolio is likely to drive Anthem’s long-term growth.
Acquisitions and collaborations have enabled ANTM to boost its Medicare Advantage growth and also strengthened its business portfolio. Momentum in Medicare and Medicaid businesses, coupled with contract wins are expected to drive Anthem’s membership. Escalating costs and a weak balance sheet, however, continue to weigh on its margins and impact financial flexibility.
(You can read the full research report on Anthem here >>>)
Shares of Infosys have gained +6.5% in the last three months against the Zacks IT Services industry’s loss of -16.6%. The Zacks analyst believes that Infosys has been benefiting significantly from large deal wins as well as momentum in digital services.
INFY’s sustained focus on Agile Digital and artificial intelligence-driven Core services is a tailwind. Strong demand for its services in cloud, Internet of Things, cyber security, data and analytics is a key driver. Steadily rising anti-outsourcing sentiments in certain parts of the world, higher subcontractor costs and Infosys’ compensation revision have been weighing on margins, though.
(You can read the full research report on Infosys here >>>)
Other noteworthy reports we are featuring today include Norfolk Southern Corp. (NSC) and Chipotle Mexican Grill, Inc. (CMG).
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +25.3% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.